Biotech Values

[DewDiligence]

AGN/VRX—Good piece from the NYT’s DealBook column on the groundbreaking nature of the proposed deal, the unusual machinations that underpinned it, and what AGN’s options are now (a poison pill has already been implemented [#msg-100963775]):

http://dealbook.nytimes.com/2014/04/22/ackman-and-valeant-bid-45-6-billion-for-botox-maker

The VRX/Pershing oral presentation on the proposed deal yesterday lasted four hours (!), but there is apparently no webcast replay; the 65-page slide deck can be viewed at http://ir.valeant.com/investor-relations/events-and-presentations/default.aspx .